Fig. 7

Clinical relevance and schematic mechanism of HUMT in TNBC. a, b Correlation between HUMT, YBX1, and FOXK1 in clinical TNBC samples of SYSUCC (N = 40). c ROC analysis of OS for AJCC T stage [AUC = 0.651 (95%CI, 0.558–0.743)], N stage [AUC = 0.641 (95%CI, 0.540–0.742)], HUMT [AUC = 0.724 (95%CI, 0.652–0.795)], and combined panel [AUC = 0.808 (95%CI, 0.739–0.877)]. d ROC analysis of DFS for AJCC T stage [AUC = 0.658 (95%CI, 0.567–0.749)], N stage [AUC = 0.683 (95%CI, 0.587–0.780)], HUMT [AUC = 0.715 (95%CI, 0.643–0.788)], and combined panel [AUC = 0.816 (95%CI, 0.750–0.882)]. e WB analysis showed a higher level of FOXK1 in patients with lymph node metastatic TNBC. f The proposed mechanism of HUMT in this study